摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(3-chlorophenyl)isoquinolin-1-amine | 883798-23-0

中文名称
——
中文别名
——
英文名称
N-(3-chlorophenyl)isoquinolin-1-amine
英文别名
N-(3-chlorophenyl)isoquinoline
N-(3-chlorophenyl)isoquinolin-1-amine化学式
CAS
883798-23-0
化学式
C15H11ClN2
mdl
——
分子量
254.719
InChiKey
FGIMGULGLNPSCU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    24.9
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    N-(3-chlorophenyl)isoquinolin-1-amine碘苯二乙酸对甲苯磺酸间氯过氧苯甲酸 作用下, 以 为溶剂, 反应 6.0h, 以72%的产率得到10-chlorobenzo[4,5]imidazo[2,1-a]isoquinoline
    参考文献:
    名称:
    Hypervalent iodine(iii) catalyzed oxidative C–N bond formation in water: synthesis of benzimidazole-fused heterocycles
    摘要:
    一种多样的苯并咪唑并杂环化合物被合成,通过原位生成的高价碘(III)催化的分子内氧化C-N键形成,在水中和常温下进行。
    DOI:
    10.1039/c4ra02279c
  • 作为产物:
    描述:
    碳酸亚乙烯酯N-(3-chlorophenyl)benzamidinezinc(II) sulfate heptahydratedichloro(pentamethylcyclopentadienyl)rhodium (III) dimersilver(I) acetate 作用下, 以 氯苯 为溶剂, 反应 24.0h, 以60%的产率得到N-(3-chlorophenyl)isoquinolin-1-amine
    参考文献:
    名称:
    通过 Rh 催化的苯甲酰胺与碳酸亚乙烯酯的 [4 + 2] 环化合成氨基异喹啉
    摘要:
    开发了一种用于合成 1-氨基异喹啉衍生物的新策略。这种 Rh(III) 催化的 [4 + 2] 环化反应使用苯甲脒作为有效的导向基团,使用碳酸亚乙烯酯作为乙炔替代物。此外,该反应底物范围广,收率好,只产生碳酸根阴离子作为副产物。
    DOI:
    10.1016/j.cclet.2021.04.058
点击查看最新优质反应信息

文献信息

  • Methods and compositions for the treatment of pain, inflammation and cancer
    申请人:Barbosa Joseph
    公开号:US20080194557A1
    公开(公告)日:2008-08-14
    This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods.
    本发明涉及用于治疗、管理和预防疼痛、炎症、癌症和眼部疾病和障碍的方法,以及在这些方法中有用的化合物和制药组合物。
  • Methods and compositions for the treatment of body composition disorders
    申请人:Barbosa Joseph
    公开号:US20080200458A1
    公开(公告)日:2008-08-21
    This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.
    本发明涉及治疗、管理和预防身体组成失调的方法,以及在这些方法中有用的化合物和制药组合物。
  • Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model
    作者:Maud Bollenbach、Claire Lugnier、Mélanie Kremer、Eric Salvat、Salim Megat、Frédéric Bihel、Jean-Jacques Bourguignon、Michel Barrot、Martine Schmitt
    DOI:10.1016/j.ejmech.2019.05.026
    日期:2019.9
    Neuropathic pain is a chronic pain caused by a lesion or disease affecting the somatosensory nervous system. To date, no specific treatment has been developed to cure this pain. Antidepressants and anticonvulsant drugs are used, but they do not demonstrate universal efficacy, and they often cause detrimental adverse effects. Some studies highlighted the efficacy of sildenafil, a well-known inhibitor of phosphodiesterase 5 (PDE5, (IC50=3.3 nM)), in models of pain. Based on these results, we focused our attention on MY 5445, another known PDE5 inhibitor. Homologues, isosteres and structural analogues of MY 5445 were designed and all synthesized compounds were evaluated for their inhibitory activity toward PDE5. Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment. (C) 2019 Elsevier Masson SAS. All rights reserved.
  • WO2008/89307
    申请人:——
    公开号:——
    公开(公告)日:——
  • WO2008/89310
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多